ADVAXIS INC (ADXS) Stock Price & Overview
NASDAQ:ADXS
Current stock price
The current stock price of ADXS is 0.155 null. Today ADXS is down by -35.42%. In the past month the price decreased by -61.41%. In the past year, price decreased by -59.74%.
ADXS Key Statistics
- Market Cap
- 22.574M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.20
- Dividend Yield
- N/A
ADXS Stock Performance
ADXS Stock Chart
ADXS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ADXS. When comparing the yearly performance of all stocks, ADXS is a bad performer in the overall market: 98.63% of all stocks are doing better.
ADXS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ADXS. Both the profitability and financial health of ADXS have multiple concerns.
ADXS Earnings
ADXS Forecast & Estimates
7 analysts have analysed ADXS and the average price target is 2.3 null. This implies a price increase of 1380.65% is expected in the next year compared to the current price of 0.155.
ADXS Groups
Sector & Classification
ADXS Financial Highlights
Over the last trailing twelve months ADXS reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 58.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -581.85% | ||
| ROA | -37.01% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ADXS Ownership
ADXS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.31 | 374.127B | ||
| AMGN | AMGEN INC | 15.58 | 188.572B | ||
| GILD | GILEAD SCIENCES INC | 16.07 | 175.711B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.05 | 112.769B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.42 | 81.989B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.06 | 43.4B | ||
| INSM | INSMED INC | N/A | 34.527B | ||
| NTRA | NATERA INC | N/A | 29.881B | ||
| BIIB | BIOGEN INC | 11.02 | 26.402B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.24 | 25.496B | ||
| MRNA | MODERNA INC | N/A | 20.576B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.173B | ||
| INCY | INCYTE CORP | 12.66 | 19.083B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADXS
Company Profile
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 18 full-time employees. The company went IPO on 2005-07-28. The firm is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.
Company Info
IPO: 2005-07-28
ADVAXIS INC
9 Deer Park Drive, Suite K-1
Monmouth Junction NEW JERSEY 08540 US
CEO: Kenneth Berlin
Employees: 18
Phone: 17325451590.0
ADVAXIS INC / ADXS FAQ
What does ADXS do?
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 18 full-time employees. The company went IPO on 2005-07-28. The firm is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.
What is the stock price of ADVAXIS INC today?
The current stock price of ADXS is 0.155 null. The price decreased by -35.42% in the last trading session.
Does ADXS stock pay dividends?
ADXS does not pay a dividend.
How is the ChartMill rating for ADVAXIS INC?
ADXS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for ADXS stock?
ADVAXIS INC (ADXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.2).
How many employees does ADVAXIS INC have?
ADVAXIS INC (ADXS) currently has 18 employees.
What is the market capitalization of ADXS stock?
ADVAXIS INC (ADXS) has a market capitalization of 22.57M null. This makes ADXS a Nano Cap stock.